MIT and Microsoft researchers created an AI model to design peptide-based sensors for ultra-early cancer detection by detecting cancer-specific enzymes.
Key Details
- 1The AI model, CleaveNet, rapidly designs peptides that are efficiently and specifically cleaved by cancer-linked proteases.
- 2Nanoparticles coated with these peptides serve as in vivo sensors, releasing detectable signals in urine if target proteases are present.
- 3This approach allows non-invasive at-home cancer screening, potentially detecting and distinguishing between up to 30 cancer types.
- 4The AI-enabled sensors demonstrated high specificity for proteases such as MMP13, linked to cancer metastasis.
- 5The research appears in Nature Communications (DOI: 10.1038/s41467-025-67226-1) and is supported by ARPA-H and several foundations.
Why It Matters
AI-guided molecular sensing represents a major step towards ultra-early, highly specific cancer detection, expanding the toolkit for noninvasive diagnostics. This molecular AI approach may complement or ultimately integrate with radiology and imaging AI, enhancing multidisciplinary cancer care and research in biomarkers.
Source
EurekAlert
Related News
•EurekAlert
Stanford's SleepFM AI Predicts 130 Disease Risks from Polysomnography
Stanford researchers have developed SleepFM, an AI model that predicts over 100 diseases using one night of sleep study data.
•EurekAlert
AI-Enhanced ECGs Enable Early COPD Detection Across Large Cohorts
Mount Sinai researchers show that deep learning applied to ECGs can detect COPD early and accurately across diverse populations.
•EurekAlert
EU SHASAI Project Aims to Fortify AI Security Across Sectors
The SHASAI project will enhance AI system security through lifecycle-spanning methods tested in real-world scenarios, including healthcare.